Del Giudice Matthew Paul 4

What Happened
Matthew Del Giudice, a director of Telomir Pharmaceuticals (TELO), had a derivative transaction on 2026-05-21 in which 25,000 derivative shares (options/awards) were reported as acquired (grant) and 25,000 derivative shares were reported as disposed to the issuer the same day. No exercise price, sale price, or cash value is reported for these entries (price = N/A). This is not an open-market buy or sale of common stock but a grant and a disposition of derivative securities.

Key Details

• Transaction date: 2026-05-21; filing date: 2026-05-22 (timely filing).
• Reported amounts: 25,000 derivative shares granted (code A) and 25,000 derivative shares disposed to issuer (code D).
• Price/value: N/A — no exercise price or cash consideration disclosed in the Form 4 for these entries.
• Shares owned after transaction: not provided in the filing.
• Footnotes: F1 — the options are fully exercisable; F2 — the reporting person agreed to cancel an option granted 08/27/2024 in exchange for a new option with a lower exercise price.
• Filing timeliness: appears timely (filed the next day).

Context
These entries involve derivative securities (options/awards), not a market sale or purchase of common stock. The filing indicates a grant paired with a disposition to the issuer, and the footnote explains this relates to canceling a prior option in exchange for a new, repriced option — a common corporate action to adjust option terms. Such administrative adjustments do not necessarily indicate the director is buying or selling equity on the open market.